Noile-Immune Biotech (TSE:4893) Total Current Liabilities: 円74.41 Mil (As of Dec. 2025)


TSE:4893 Noile-Immune Biotech Inc TSE:4893
49 GF Score
Price 円136.00
GF Value 円4.34
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech Total Current Liabilities?

Noile-Immune Biotech TSE:4893 +5.43% 49 Total Current Liabilities is 円74.41 Mil as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 49/100 and a GF Value™ of 円4.34 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Noile-Immune Biotech's total current liabilities for the quarter that ended in Dec. 2025 was 円74.41

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Noile-Immune Biotech Total Current Liabilities Related Terms

Noile-Immune Biotech Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Total Current Liabilities Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial 80.48 335.18 86.26 69.44 74.41

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.08 62.84 68.64 74.41 61.05
TSE:4893
49GF Score
Noile-Immune Biotech Inc TSE:4893
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Noile-Immune Biotech's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.74+0
+Other Current Liabilities+Current Deferred Liabilities
=34.665+0
=74.41

Noile-Immune Biotech's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.74+0
+Other Current Liabilities+Current Deferred Liabilities
=34.665+0
=74.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of 円74.41 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Total Current Liabilities of 円74.41 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Total Current Liabilities too high?
Noile-Immune Biotech's current Total Current Liabilities is 円74.41 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Total Current Liabilities compare to VRTX and REGN?
Noile-Immune Biotech's Total Current Liabilities of 円74.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Total Current Liabilities is 円74.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.34, compared to a current price of 円136.00 — trading 3033.6% above its estimated fair value. The current Total Current Liabilities is 円74.41 Mil. Noile-Immune Biotech's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Total Current Liabilities is 円74.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円136.00 is trading 3033.6% above its estimated GF Value™ of 円4.34. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • Total Current Liabilities: 円74.41 Mil
  • GF Value™: 円4.34 vs. price of 円136.00 (3033.6% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
49GF Score

Get the complete analysis for TSE:4893

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円136.00
Price
円4.34
GF Value